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INTRODUCTION 
 
TUMOR INITIATION  
Experimental evidence suggests that the origin of neoplastic proliferation is predominantly 
monoclonal. The neoplastic transformation, then, is the appearance of a cell clone that, 
following an initial mutation, can prevail over the others because provided of increased 
replicative activity and / or because is refractory to the pro-apoptotic stimuli. Subsequently, 
successive genetic alterations and selective mechanisms provide new different subclones, 
many of which are able of circumvent the checkpoints of the cell cycle and to invade 
surrounding normal tissues. 
In recent years, the cancer stem cell model of tumorigenesis has received increasing 
attention. This model postulates that tumours are driven and maintained by a minority 
subpopulation of cells that have the capacity to self-renew and to generate the more 
differentiated progeny which make up the bulk of a tumour (Clarke MF et al.2006). The 
former population has been termed cancer stem cells (CSCs), tumourigenic cancer cells, or 
tumour-initiating cells, by various investigators, to indicate that only these can give rise to 
new tumours when transplanted into immuno-deficient animals (Clarke MF et al.2006).  
Evidence for the existence of CSCs initially came from studies of acute myelogenous 
leukemia (AML). Presence of CSCs have now been demonstrated in many solid tumours, 
including glioblastoma, medulloblastoma, breast cancer, melanoma, and prostate cancer 
(Takaishi S et al. 2008). The existence of CSCs has profound implications for cancer 
biology and therapy because it is likely that eradication of CSCs is the critical determinant 
in achieving cure. It has been proposed that CSCs may be particularly resistant to 
chemotherapy and radiation therapy as has been shown in a study with glioblastoma (Bao S 
et al. 2006).  
 
TUMOR PROGRESSION 
 
The carcinogenetic process may be accelerated by repeated exposures to carcinogenic 
stimuli or by selection pressures favouring the autonomous clonal derivatives.  
The stage of tumor progression is characterized by the expression of the invasive 
phenotype of tumor cells and is caused by additional morphological and behavioural 
alterations. The epithelial-mesenchymal transition (EMT) is an orchestrated series of 
events in which cell-cell and cell-extracellular matrix (ECM) interactions are altered to 
release epithelial cells from the surrounding tissue, the cytoskeleton is reorganized to 
confer the ability to move through a three-dimensional ECM, and a new transcriptional 
program is induced to maintain the mesenchymal phenotype (figure 1).  
Moreover, during progression, epithelial cells lose acquire the ability to degrade the basal 
lamina and penetrate into the surrounding stroma, to secrete pro-angiogenic factors 
(resulting in vascularization of the tumor), to invade surrounding tissues and form 
metastases. 
 
 In this new context, tumor cells alter the characteristics of the adjacent stroma to create a 
supportive microenvironment. This is strongly supported by evidence that over 80% of the 
fibroblasts demonstrate an activated phenotype in breast cancer and are named cancer 
associated fibroblasts, CAFs, (Liotta LA et al. 2001). Also our previously work 
demonstrated that fibroblasts induce considerable proteomic modulations on 8701-BC cell 
line when cocultured, mainly in the cytoskeleton proteins and glycolytic enzymes. 
Additionally, fibroblast-conditioned medium increased neoplastic cell proliferation and 
invasion; suggesting that fibroblast stimulation may enhance the malignant potential or 
breast cancer cells in vitro (Cancemi P. et al 2010). 
It has been shown that fibroblasts play major roles in tumor invasion by secreting various 
matrix-degrading proteases as well as their activators such as uPA (Camps JL et al. 1990). 
uPA can cleave MMPs to activate these proteins, and up-regulation of MMPs activity 
results in significant ECM degradation, which contribute to angiogenesis and metastasis. 
Figure 1: Epithelial-Mesenchymal Transition (EMT) and Epithelial Plasticity. Tight junctions which 
typically maintain apico-basal polarity dissolve allowing the mixing of apical and basolateral membrane 
proteins, adherens and gap junctions are disassembled and cell surface proteins such as E-cadherin and 
epithelial-specific integrins (green) are replaced by N-cadherin and integrins specific to extracellular 
components (blue). The actin cytoskeleton is remodeled into stress fibers which accumulate at areas of 
cell protrusions. The epithelial intermediate filaments, cytokeratins, are replaced by vimentin. 
Meanwhile, the underlying basement membrane is degraded and the cell invades and moves into the 
surrounding stroma, devoid of cell-cell contacts. 
The tissue inhibitors of metalloproteinases (TIMPs) have been shown to down-regulate 
MMPs activity. TIMPs can also regulate other growth factors indicating that TIMPs may 
also be involved in some important oncogenic signal pathways (Flavell SJ et al. 2008). 
 
 
WARBURG EFFECT 
 
It is now emerging that the tumor microenvironment influences the rate of cell 
proliferation and may have a profound effect on tumor progression and resistance to 
therapy (Hoogsteen IJ et al. 2007).  
In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative 
phosphorylation to generate the energy needed for cellular processes, most cancer cells 
instead rely on aerobic glycolysis, a phenomenon termed ―Warburg effect‖, because 
described by Otto Warburg. 
 
 
Figure 2: Schematic representation of the differences between oxidative phosphorylation, anaerobic 
glycolysis, and aerobic glycolysis (Warburg effect). 
It is only under anaerobic conditions that differentiated cells produce large amounts of 
lactate (figure 2). In contrast, most cancer cells produce large amounts of lactate regardless 
of the availability of oxygen and hence their metabolism is often referred to as ―aerobic 
glycolysis‖. Warburg originally hypothesized that cancer cells develop a defect in 
mitochondria that leads to impaired aerobic respiration and a subsequent reliance on 
glycolytic metabolism. However, subsequent work showed that mitochondrial function is 
not impaired in most cancer cells, suggesting an alternative explanation for aerobic 
glycolysis in cancer cells. 
One proposed explanation for Warburg‘s observation is that tumor hypoxia selects for cells 
dependent on anaerobic metabolism (Gatenby RA et al. 2004). Tumors are characterized 
by gradients of O2 levels, based on the distance of tumor cells from a functional blood 
vessel. Tumor cells surrounding the blood vessel are well oxygenated, whereas the tumor 
cells more distant from the vessel are poorly oxygenated and express high levels HIF-1. 
Several evidences suggested the existence of a ―metabolic symbiosis‖ between hypoxic 
and aerobic cancer cells, in which lactate produced by hypoxic cells is taken up by aerobic 
cells, which use it as their principal substrate for oxidative phosphorylation (figure 3).  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Although the altered metabolism in cancer has been well documented, the exact 
mechanisms leading to increased glycolysis and abnormal tumor cell growth under 
hypoxic conditions are not completely understood. A possible link could be the "early 
response" gene c-myc, because of its frequent overexpression in transformed cells, its 
stimulatory effect on cell growth (Hurlin PJ et al. 2004), and ability to upregulate the 
transcription of several glycolytic enzymes (Osthus RC et al. 2000) Myc is overexpressed 
in approximately 70% of all human tumors (Gordan JD et al. 2007), and activate α-enolase 
(48 KDa), a glycolytic enzyme which catalyzes the conversion of 2-phosphoenolpyruvate 
from 2-phosphoglycerate (Kim JW et al. 2005). Moreover, α-Enolase is also a hypoxic 
stress protein, which may contribute to hypoxic tolerance of tumors by increasing 
anaerobic metabolism (Pancholi V, 2001). 
 
Figure 3: Intratumoral hypoxia and metabolic symbiosis. Hypoxic cells express high levels of  which 
induces the expression of proteins that increase: uptake of glucose (e.g., glucose transporter 1 [GLUT1]); 
conversion of glucose to pyruvate (e.g., glycolytic enzymes [Glyc. Enz.]); generation of lactate and H+ 
(e.g., LDHA); and efflux of these molecules out of the cell (e.g., carbonic anhydrase IX [CA9], sodium-
hydrogen exchanger 1 [NHE1], MCT4). The lactate produced by hypoxic cells is taken up by aerobic 
cells, which use it as their principal substrate for oxidative phosphorylation. 
HYPOXIA AND ANGIOGENESIS 
 
As a result of variable blood flow (oxygen supply) and rapid utilization of glucose within 
solid tumors (oxygen utilization), most tumor cells are subjected to a microenvironment 
that is hypoxic. Hypoxia is quite common in breast cancer where it has been related to poor 
prognosis (Vleugel MM et al. 2005) with increased risk for tumor recurrence and 
metastasis. 
The hypoxic response is significantly controlled in most cells by HIF-1, a heterodimeric 
transcription factor composed of the nearly ubiquitous HIF-1α and its dimerization partner 
HIF-1β. HIF-1 activates approximately 200 genes encoding proteins that regulate cellular 
metabolism, proliferation, motility, haematopoiesis, and angiogenesis (Semenza GL, 
2000). Upon initiation of the hypoxic signal, HIF1-α translocates to the nucleus, dimerizes 
with HIF1-β to form the HIF-1 complex and induces the expression of its transcriptional 
targets via binding to hypoxia-responsive elements (HREs) (Chilov D et al. 1999).  
In response to various alterations in the microenvironment, and in particular, to 
intratumoral hypoxia, angiogenesis-stimulating factors produced by the cells themselves 
induce the formation of new blood vessels from 
pre-existing vasculature, to increase delivery of 
oxygen and nutrients to tissues (figure 4). Many 
angiogenic genes, such as VEGF, angiopoietin-2, 
VEGF receptors (Flt1 and KDR), and neuropilin-
1 (Hickey MM et al. 2006; Simons M, 2005) are 
induced by hypoxia by several mechanisms, 
including direct transcriptional activation by 
Figure 4: schematic representation of 
formation of new blood vessels from pre-
existing vasculature. 
HIFs or indirect up-regulation by HIF-induced molecules. In addition, other transcription 
factors induced by hypoxia, such as Related Transcription Enhancer Factor-1 (RTEF-1) 
and early growth response 1 (EGR-1), can both target VEGF to enhance angiogenesis 
(Shie JL et al. 2004; Yan SF et al. 2000). Additional angiogenic growth factors such as 
IGF are also induced by hypoxia, but can signal through a HIF-1-independent pathway 
(Slomiany MG et al. 2006).  
However, unlike normal tissues, the newly formed vascular network has a number of 
"defects", both structural and functional (expansion, basement membranes and endothelial 
surfaces incomplete or absent, irregular and tortuous architecture, arterio-venous shunts, 
blind ends and lack of contractile components of the wall) (Vaupel et al., 1989) resulting in 
an irregular blood flow sometimes reducing the transport of oxygen and nutrients to cancer 
cells.  
 
BREAST CANCER 
 
Breast cancer is the leading cause of cancer-related death in women world-wide.  
About 90% of solid tumors is part of the category named carcinoma that is cancer of 
epithelial-glandular origin with high degree of malignancy. In breast cancer we can 
distinguish: 
carcinoma in situ (non-infiltranting) characterized by 
uncontrolled proliferation of malignant epithelial cells 
that do not exceed the basement membrane; this 
proliferation can occur within the lobule (lobular 
carcinoma in situ, LCIS) or into the duct (ductal 
carcinoma in situ, DCIS). 
Infiltrating breast cancer is a heterogeneous disease in its 
presentation, pathological classification and clinical 
course. It‘s characterized by the overcoming of the 
epithelial cells of the basal lamina and the ability to invade different anatomical regions 
from that of tumor formation. 
 
 
MOLECULAR BASIS OF BREAST CANCER 
 
Despite significant advances in diagnosing and treating breast cancer, several major 
unresolved clinical and scientific problems remain. 
While the exact etiology of breast cancer is unknown, family history is one of the strongest 
determinants of risk, implying hereditary factors. Some observations suggest that 5-10% of 
Figure 5: Malignant tumor 
infiltrating [T], characterized by 
initial intraductal proliferation of 
cancer cells with typical area of 
central necrosis [N]. 
all cases of breast cancer may have a hereditary basis (Yoshida and Miki, 2004). The two 
genes that confer susceptibility to the onset of cancer breast are BRCA 1, BRCA 2 that 
belong to tumor suppressor family. In particular BRCA1 gene is located on the long arm 
(q) of chromosome 17 and BRCA2 gene is located on the arm (q) along chromosome 13. 
Although the structures of the BRCA1 and BRCA2 are very different, some functions of 
the two genes are related; indeed the correspondent proteins are essential for the repair of 
damaged DNA. Moreover women with a mutation at one of the two genes have, in fact, 
about 60-80% chance of developing breast cancer during their lifetime.  
In the sporadic cases of breast cancer, alterations of protooncogenes are associated with the 
initiation, promotion, and/or maintenance of tumors. Oncogenes often found to be 
overexpressed in human breast cancer tissue include members of the myc and ras family 
(c-myc, Ha-ras-1), the members of the EGF receptor (EGFR, erbB) family, including erbB-
2 (or HER-2 or neu), HER-3, and HER-4. Overexpression and mutation often leads to 
constitutive activation of these receptors (ie, signaling in the absence of their cognate 
ligands). Growth-promoting signals may be continuously transmitted into the cells, 
resulting in activation of multiple intracellular signal transduction pathways and 
unregulated cell growth. Genes normally involved in cell cycle control, especially 
members of the cyclin D family, may also function as oncogenes. 
Several studies have shown that blockade of these growth factor receptors or pathways has 
therapeutic implications: for example, both in preclinical models and in human breast 
cancer, monoclonal antibodies to EGFR or HER-2 have dramatic antitumor effects. 
Furthermore, these antibodies have synergistic interactions with cytotoxic agents, such as 
the anthracyclines, the platinum analogs, and the taxanes (Baselga J et al. 1994).  
In addition to BRCA1 and BRCA2, alterations in two known suppressor genes, the 
retinoblastoma gene (RB1) and the human p53 gene, have been identified in human breast 
cancer cells, as well as in other solid tumors. Mutations in the p53 gene have been found in 
families with the Li-Fraumeni syndrome, who have a markedly increased incidence of 
breast cancer and other neoplasms. In addition, up to 50% of breast cancers have been 
shown to have mutations in the p53 gene.  
Evaluation of mutational inactivation of suppressor genes, associated with breast cancer, 
could lead to early recognition of high-risk families, as well as to new treatment strategies 
to reverse the malignant phenotype by introducing normal gene copies through gene 
therapy or by treatment with the normal suppressor protein itself. 
 
 
CLINICAL CLASSIFICATION OF BREAST CANCER 
 
Breast cancer is a clinically heterogeneous disease, and existing histological classifications 
do not fully capture the varied clinical course of this disease. Immunohistochemistry (IHC) 
currently forms the cornerstone of molecular classification of breast cancer into ER-
positive and ER-negative categories. Nucleic acid in situ hybridization is now also 
routinely used to classify breast cancer into HER-2 amplified or non-amplified categories. 
A large number of other single gene molecular markers were also assessed in the past 25 
years using these technologies but failed to establish themselves in the clinic for various 
reasons. 
Estrogen receptor: ER (α) expression is undoubtedly the most important biomarker in 
breast cancer, because it provides the index for sensitivity to endocrine treatment. ER-
positive tumors (c. 80% of breast cancer) use the steroid hormone estradiol as their main 
growth stimulus; ER is therefore the direct target of endocrine therapies. While the absence 
or presence of the ER is used to obtain treatment decisions, little attention has been paid on 
the value of the quantitative expression levels as a predictive indicator. 
There have also been investigations concerning the amplification of the ER gene (ESR1). 
An initial report indicated that ESR1 gene amplification in breast cancer could be detected 
in 20% of all invasive tumors, and that there was a correlation between the gene 
amplification and ER expression levels (Holst et al. 2007). However, <3% of invasive 
breast cancer cases were reported as ESR1 amplified by other independent groups (Brown 
et al. 2008). 
Progesterone receptor: The expression of the PgR is strongly dependent on the presence of 
ER. Tumors expressing PgR but not the ER are uncommon and represent <1% of all breast 
cancer cases in some large series (Viale et al. 2007). There is evidence that in metastatic 
breast cancer the response to anti-estrogen treatment is better among patients with tumors 
expressing both ER and PgR versus those who only show ER positivity but lack the PgR 
expression (Elledge et al. 2000). 
HER2: the oncogene HER2 was first identified to be an indicator of patient‘s prognosis. In 
cases of HER2 being overexpressed (HER2 positive), breast cancer patients are more 
likely to suffer from relapse and tend to have a shorter overall survival. Through the 
development of the monoclonal antibody trastuzumab, which is targeted at HER2, the 
amplification status of HER2 became also a highly predictive biomarker (Slamon et al. 
1987, Mass et al. 2005). Overexpression and amplification of HER2 can be detected in 
about 15% of all primary breast cancer, and this group of patients benefit significantly 
from anti-HER2 therapies. 
Within the last few years, many more promising agent targeting HER2 have been 
developed including monoclonal antibodies and tyrosine kinase inhibitors. From them, 
HER2 status is likely to be a predictive markers as well (Widakowich et al.2008). The 
preliminary finding that patients expressing a truncated cytoplasmic HER2 receptor 
(p95HER2) show a poor response to trastuzumab (Anido et al.2006), but may benefit from 
the tyrosine kinase inhibitor lapatinib (Scaltriti et al. 2007), might have some implications 
for future HER2 testing. 
Ki67: is a nuclear non histone protein. The characteristic that Ki67 was universally 
expressed among proliferating cells and absent in quiescent cells led to the further 
evaluation of Ki67 as a marker of proliferation. Although little is known about the exact 
function of the protein in cell division, Ki67 is expressed during G1, S, and G2 phases of 
cell cycle with a peak during mitosis and an absence in G0 phase (Lopez et al.1991) 
The correlation of Ki67 and other biomarkers in invasive breast cancer has been studied 
intensively. Unsurprisingly, given that the Nottingham grading system defines mitotic rate 
as one of its three criteria (Trihia et al. 2003), there is a good correlation with tumor grade. 
The relationship with ER has been predominantly described as an inverse correlation with 
lower proliferative activity in ER-positive tumors (Haerslev et al. 1996). There are hints of 
a correlation with HER2 as well, but this is not completely defined (Nicholson et al. 1993, 
Rudolph et al. 1999). 
 
Although determination of ER status is an essential part of the diagnostic workup of all 
breast cancer patients (useful to determine whether a patient is a candidate for endocrine 
therapy or not) these current clinical parameters, for breast cancer diagnosis, cure, and 
prognostic/ predictive properties, appear inadequate to discriminate between cancer 
subtypes and to support proper therapeutic decisions. Indeed, patients with the same type 
and stage of disease often display significantly different clinical outcome and responses to 
therapy. Moreover, patients with tumors that lack expression of estrogen receptor (ER), 
progesterone receptor (PR), and HER2 amplification (triple negative breast cancer) are not 
candidate for currently available FDA-approved, target therapies and therefore treated with 
standard chemotherapy regimens. 
 
 
MOLECULAR CLASSIFICATION OF BREAST CANCER 
 
The advent of high throughput gene-expression profiling technologies allowed 
investigators to ask how many different molecular subtypes of breast cancer exist based on 
complex mRNA expression patterns. It might be useful to identify the various molecular 
classes because the different subsets may have different natural histories. Also, the 
molecular signatures that define particular groups may lead to the discovery of new 
therapeutic targets and treatments that are effective in particular molecular subsets. The 
first study to examine comprehensive gene-expression patterns of breast cancer have 
revealed five major molecular subtypes of breast cancer: basal-like, luminal A, luminal B, 
HER2+/ER–, and normal breast–like. The molecular differences result in distinct clinical 
outcomes and responses to treatment; in general, the basal-like tumors have the worst, and 
luminal A-type tumors the best, prognosis (Sorlie T et al. 2001). 
The luminal subtypes of breast cancers express high amounts of luminal cytokeratins and 
express genetic markers of luminal epithelial cells and normal breast cells (Rakha EA et 
al.2007; Sotiriou C and Pusztai L, 2009). In contrast, basal-like breast cancers tend to 
express cytokeratins associated with basal types of cancers, as they arise from the outer 
basal layer. Basal-like breast cancers are typically high-grade and poorly differentiated 
when examined morphologically. It has also been reported that almost 82% of basal-like 
breast cancers express p53 compared with 13% in the luminal A subgroup (Sørlie T et al. 
2001). Ongoing studies have recently identified a new and intriguing subtype called 
―claudin-low‖, characterized by the low to absent expression of luminal differentiation 
markers, high enrichment for epithelial-to-mesenchymal transition markers, immune 
response genes and cancer stem cell like features (Prat A et al. 2010). 
The above mentioned five molecular subtypes of breast cancer are conserved across ethnic 
groups and are already evident at the ductal carcinoma in situ (DCIS) stage (Yu K et 
al.2004), suggesting distinct tumor progression pathways for each tumor type. Distinct cell 
of origin (e.g., cancer stem cells) and tumor subtype–specific genetic and epigenetic events 
are two possible, not necessarily mutually exclusive, explanations of this extensive intra- 
and intertumoral heterogeneity. Based on the cell of origin hypothesis, each tumor subtype 
is initiated in a different cell type presumably stem or progenitor cell (figure 6A), whereas 
according to the model depicted in figure 6B, the cell of origin can be the same for 
different tumor subtypes and the tumor phenotype is primarily determined by acquired 
genetic and epigenetic events.  
 
Figure 6: Hypothetical models explaining breast tumor subtypes. Cell of origin (A) and tumor subtype–
specific transforming event (B) models.  
 
GENE-EXPRESSION-BASED PROGNOSTIC ASSAYS FOR BREAST CANCER 
 
Several gene signatures for prognostic purpose are now available for prognostication of 
patients diagnosed with breast cancer. The basic premise of these emerging tests is that 
they simultaneously quantify the expression of multiple genes and combine the gene 
expression measurements into prediction scores that may predict clinical outcome more 
accurately than any of the genes alone. 
Mammaprint 
MammaPrint® (Ach RA et al, 2007) was originally developed as a general prognostic test 
in premenopausal untreated patients. Original discovery of prognostic genes was from a 
microarray analysis of relative expression levels of 25,000 genes in relationship to a 
universal reference RNA in tumors from a cohort of 78 premenopausal patients younger 
than 55 years without nodal metastasis who received no systemic therapy. By associating 
expression of each gene with clinical outcome, a prognostic algorithm based on the 
expression levels of 70 genes was established (van 't Veer LJ et al. 2002). 
Clinical utility of the MammaPrint® assay is currently being tested in a randomized 
clinical trial called MINDACT (Microarray In Node-Negative and 1 to 3 positive lymph 
node Disease may Avoid Chemo Therapy) (Cardoso F et al. 2008). 
Oncotype DX® was developed specifically as a prognostic and predictive test for the 
benefit of chemotherapy in women with node-negative, ER positive breast cancer who 
have been treated with tamoxifen. This signature is a combined score of 16 genes of 
interest. Of note, this score is a gene expression signature derived using quantitative RT-
PCR, on RNA extracted from paraffin- embedded tissues. The associated clinical trial for 
this test, is TAILORx—Trial Assigning IndividuaLized Options for Treatment (Rx) 
(Zujewski JA and Kamin L, 2008). 
Several criticisms, questions and perspectives have been raised regarding the prognostic 
gene signatures reported so far. First, some argue that most of the signatures only add little 
information compared to an optimal clinical-pathological score that would include ER, 
Her2 and Ki67 in addition to the conventional clinical parameters (de Azambuja E et al. 
2007). Another criticism relates to the fact that most of the predictors were generated using 
a mix of molecularly heterogeneous tumours. 
In conclusion, although these tests allow an increase in the rate of patients who could be 
spared adjuvant chemotherapy while still correctly identifying the high-risk patients, they 
present some limitations that will have to be taken into account to generate more accurate 
‗second generation' gene signatures (Desmedt C et al. 2008). 
CANCER BIOMARKERS 
 
Every cell type has a unique molecular signature, referred to as biomarkers, which are 
identifiable characteristics such as levels or activities (the abilities of genes or proteins to 
perform their functions) of a myriad of genes, proteins or other molecular features. 
Tumor biomarkers are molecules often produced by the tumor itself or the host system in 
response to the tumor and provide the biological material to determine the risk of getting 
cancer, to detect cancer, to classify cancer, or to provide insight into prognosis and 
therefore a therapeutic advantage. Tumor biomarkers include cancer-specific mutations or 
changes in gene expression or promoter methylation, which can result in alterations in 
protein expression (Tainsky MA, 2009). 
Establishment of biomarkers requires a comprehensive understanding of the molecular 
mechanisms and cellular processes underlying the initiation of cancer, especially focusing 
on how small changes in only a few regulatory genes or proteins can disrupt a variety of 
cellular functions.  
 
 
CURRENT CLINICAL BIOMARKERS 
 
Diagnostic and prognostic biomarkers may help clinical oncologists to (i) identify who is 
at risk, (ii) diagnose at an early stage, (iii) select the best treatment modality, and (iv) 
monitor response to treatment (Ludwig JA et al. 2005). 
 
 
 
Genetic and epigenetic biomarkers 
Duplication/ deletion/ mutation of genomic material is predominantly responsible for 
oncogenic transformation because induce gain/ loss of gene function. Unfortunately, 
random chromosomal abnormalities are not associated with a particular morphological 
change give rise to clinical cancer. On the contrary, non-random mutations, and 
translocations/ rearrangement within the regulatory region of the gene serve as highly 
specific tumour markers for unique clinical diagnosis. For example, the ―Philadelphia 
chromosome‖ is associated with chronic myelogenous leukaemia due to a translocation 
between chromosomes 9 and 22. Other examples occur in Burkitt‘s lymphoma and in 
follicular B-cell lymphomas.  
In recent years it has become apparent that epigenetic events (occur directly through DNA 
methylation of genes or indirectly by methylation, acetylation, or phosphorylation of 
histones and other proteins around which DNA is wound to form chromatin) are 
potentially responsible for cancer initiation and progression as genetic abnormalities, with 
DNA hypo- and hyper-methylation promoting cancer development. Genomic 
hypomethylation may lead to both genomic instability and stronger gene expression. On 
the other hand, hypermethylation induces the functional silencing of tumour suppressor 
genes. For example, hypermethylation of APC gene is utilized to determine the stage of 
oesophageal cancer, detect recurrent disease, and monitor disease progression or treatment 
response (Arnold K et al. 2000). Moreover, high level of hypermethylated APC gene in the 
bloodstream is generally associated with poor survival (Puig PL et al.1998). 
 
Protein biomarkers  
The cancer proteome contains information on perhaps every biological process that takes 
place in cancer cells, cancer tissue microenvironment, and cancer cell-host interaction. 
Cancer cells release many proteins and other macromolecules into the extra-cellular fluid 
through secretion that can also serve as biomarkers. Some of these products can end up in 
the bloodstream and hence serve as potential serum biomarkers. Some important cancer 
antigens that serve as diagnostic and prognostic biomarkers of cancer are summarized in 
the Table 1. 
 
 
As already described above breast cancer treatment has experienced several changes in the 
past decades due to the discovery of specific prognostic and predictive biomarkers that 
enable the application of more individualized therapies to different molecular subgroups. 
Among the diagnostic biomarkers most commonly used for breast cancer we find: 
 
• CEA Carcinoembryonic antigen is a 200 kDa glycoprotein that acts as a cell-cell 
adhesion molecule, normally expressed in fetal tissues and was among the first 
identified tumor biomarkers. CEA is a biomarker that is elevated in a variety of 
cancers including colorectal, breast, lung, or pancreatic cancer.  
• CA 15.3 protein is a member of the family of proteins known as mucins, whose 
normal function is cell protection and lubrication. It plays a role in reducing cell 
adhesion and is found throughout the body. Elevated levels of this antigen are found 
mainly in breast cancer where it appears to be involved in metastasis (Duffy MJ 
1999). Pre-operative concentration of CA15-3 is associated with worse prognosis 
than those with low concentrations (Park BW et al. 2008). 
• MUC1 is a large, heavily glycosylated protein that is embedded normally in the 
apical membrane of many secretory organs, such as salivary glands, breast, and lung. 
Glycosylation of MUC1 reduce intercellular interactions between adjacent tumor 
cells because sterically impeded adhesion (Wesseling J et al.1995,1996). Moreover, 
the cytoplasmic domain of MUC1 could compete for and bind to the β-catenin 
molecule, inhibiting E-cadherin-mediated intercellular adhesion (Li Y et al. 1998). 
These evidence suggest that MUC1 may facilitate tumor invasion and metastases 
and, consequently, may be associated with biologically aggressive tumors and a 
worse prognosis. 
• PSA Prostate specific antigen is a 33 kDa serine protease belonging to the family of 
―Kallikrein genes‖ and produced by both normal as well as neoplastic prostate 
epithelial cells is the most widely studied biomarker in prostate cancer. Being a 
protease, it appears to be involved in the initiation and growth of prostate cancer by 
abnormal release of growth factors or proteolysis of growth factor binding proteins. 
It may also have a role in invasion and metastases through the degradation of 
collagen and laminin. 
 
 
 
POTENTIAL CLINICAL BIOMARKERS 
 
Today there is a need to find new biomarkers able to predict a correct diagnosis and allow 
better stratification of patients for targeted therapy. An ideal tumor marker should have a 
high degree of diagnostic accuracy, and should be characterized by analytical reliability of 
assessment methods, diagnostic specificity (diagnosis of cancer, tumor localization) and 
diagnostic sensitivity (early detection of cancer). Prognostic factors intend to predict 
objectively and independently patient clinical outcome independent of treatment, while 
predictive factors aim to predict the response of a patient to a specific therapeutic 
intervention and are associated with tumor sensitivity or resistance to that therapy. In 
general, prognostic markers help to determine whether a patient requires treatment, and a 
predictive factor is useful in deciding which treatment will be the best. 
 
Cells biomarkers  
In advanced stages of tumours, cells starts appearing in bloodstream where it can be easily 
monitored. Advanced clinical practice in certain malignancy have effectively used tumour 
and immune cells where it served as a good biomarker of prognosis. 
Circulating Tumor Cells (CTCs) :The presence of CTCs has been shown to predict 
survival in patients with metastatic breast cancer at multiple time points throughout the 
course of therapy (Ring A. et al. 2004). CTCs provide an early, reliable indication of 
disease progression and survival for patients on systemic therapy for metastatic breast 
cancer. Elevated CTCs at any time during therapy is a harbinger of progression, while 
elimination of CTCs indicates effectiveness of the therapy (Cristofanilli M. et al.2004). 
CTCs have been shown to be superior to standard tumour markers in predicting prognosis. 
Furthermore, the efficacy or benefit to systemic therapy can also be predicted by the level 
of CTCs as early as 3-4 week after initiation of therapy. Patients with persistent CTCs (≥ 
5) demonstrate lack of response to treatment or progressive disease at the time of restaging 
by standard imaging modalities, while objective remission have been reported in patients 
with < 5 CTCs. Available evidences clearly suggest that CTCs can be used as an early 
predictor of treatment efficacy and extremely useful in sparing patients from futile therapy 
early in the course of their treatment (Cristofanilli M. et al.2005). 
Others important promising cell types as biomarker are the Cancer stem cells (CSCs): 
Identify and characterize CSCs is of paramount importance and will likely lead to new 
therapeutic avenues. Using mice models, Al-Hajj et al. found that only a minority of breast 
cancer cells had the ability to form new tumors. They were able to distinguish the 
tumorigenic (tumor initiating stem cells) from the nontumorigenic cancer cells based on 
cell surface marker expression. They prospectively identified and isolated the tumorigenic 
cells as CD44
+
CD24
-
 that show to express higher levels of proinvasive genes and have 
highly invasive properties (Al-Hajj M et al. 2003). 
Another candidate marker of CSC is aldehyde dehydrogenase 1 (ALDH1), a detoxifying 
enzyme responsible for the oxidation of intracellular aldehydes (Duester G, 2000); ALDH 
may have a role in early differentiation of stem cells, through its role in oxidizing retinol to 
retinoic acid (Chute JP et al., 2006). Increased ALDH activity has also been found in stem 
cell populations in multiple myeloma and acute myeloid leukemia (AML) (Matsui W et al., 
2004; Pearce DJ et al., 2005). ALDH activity may thus provide a common marker for both 
normal and malignant stem and progenitor cells. Ginestier C et al., showed that normal and 
cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity 
(ALDH) have stem/progenitor properties (Ginestier C et al. 2007). 
T-regulatory cells: It is becoming increasingly clear that regulatory T cells (T-regs) are 
equally important in inducing and maintaining peripheral self-tolerance and thus 
preventing immune pathologies (Sakaguchi S, 2004; Maloy KJ and Powrie F, 2001). 
Furthermore, studies in cancer patients suggests that increased T-regs activity may be 
associated with poor immune responses to tumour antigens and contribute to immune 
dysfunction resulting in tumour growth (Liyanage UK et al 2002; Siddiqui SA et al 2007). 
High numbers of T-regs have been found in lung, pancreatic, breast, liver and skin cancer 
patients, either in the blood or in the tumour itself (Woo EY et al. 2002; Wolf AM et al. 
2003; Viguier M. et al 2004; Ormandy LA et al. 2005). 
 
Serum autoantibodies 
Immunosurveillance to cancer cells is triggered to initiate antigen-specific tumor 
destruction (Baldwin RW, 1966; Baldwin RW 1967). The autologous proteins of tumor 
cells, commonly referred to as TAAs, are thought to be altered in a way that renders these 
proteins immunogenic. These self-proteins could be overexpressed, mutated, misfolded, or 
aberrantly degraded such that autoreactive immune responses in cancer patients are 
induced (e.g. HER2⁄ neu, p53 and ras) (Ward RL et al 1999). TAAs that have undergone 
post-translational modifications (PTMs, e.g. glycosylation, phosphorylation, oxidation and 
proteolytic cleavage) may be perceived as foreign by the immune system (Anderson KS 
and LaBaer J 2005; Caron M et al. 2007). 
Autoantibodies possess various characteristics that enable them to be valuable early cancer 
biomarkers. First, they can be detected in the asymptomatic stage of cancer, and in some 
cases, may be detectable as early as 5 years before the onset of disease (Fernandez Madrid 
F, 2005). Second, autoantibodies against TAAs are found in the sera of cancer patients 
where they are easily accessible to screening. Third, autoantibodies are inherently stable 
and persist in the serum for a relatively long period of time because they are generally not 
subjected to the types of proteolysis observed in other polypeptides. The persistence and 
stability of the autoantibodies give them an advantage over other biomarkers, including the 
TAAs themselves, which are transiently secreted and may be rapidly degraded or cleared. 
Moreover, the autoantibodies are present in considerably higher concentrations than their 
respective TAAs; many autoantibodies are amplified by the immune system in response to 
a single autoantigen. Consequently, autoantibodies may be more readily detectable than 
their corresponding TAAs.  
 
New emerging protein biomarkers 
Cyclin D1 and Cyclin E: Cyclin D1 is overexpressed at the mRNA and protein level in 
over 50% of breast cancer cases including 15% in which a gene amplification occurs. 
While there is strong evidence that overexpression of cyclin D1 is a prognostic factor for 
better outcome in invasive breast cancer, in particular among ER-positive patients (Gillett 
et al. 1996, Hwang et al. 2003, Bilalović N et al. 2005), its amplification is associated with 
early relapse and poor prognosis (Michalides et al. 1996, Seshadri et al. 1996, Bieche et al. 
2002). Cyclin E acts similarly to cyclin D1 as a positive regulator of cell cycle transition 
with peak levels of protein expression and enzymatic complex formation with cyclin-
dependent kinase 2 in the G1 phase (Koff et al. 1992). Cyclin E gene amplification has 
been detected in several breast cancer cell lines, and there is strong evidence that cyclin E 
plays a role in tumorigenesis (Buckley et al. 1993). 
S100 proteins: One group of proteins that is emerging as a potentially important group of 
markers in multiple tumour types is the S100 family. There is increasing evidence that 
altered expression of S100 family members is seen in many cancers including breast, lung, 
bladder, kidney, thyroid, gastric, prostate and oral cancers. S100 proteins are commonly 
up-regulated in tumours and this is often associated with tumour progression. The 
association between S100 family members and tumors can be explained for several 
reasons: firstly, the region of human chromosome 1q21, where most of S100 genes are 
clustered, is prone to genomic rearrangements, likely supporting the tumor progression 
(Santamaria-Kisiel L et al 2006; Salama I, 2008); secondly, several S100 members show 
altered expression levels in cancer cells compared to normal cells and are differentially 
expressed in various malignancies, according to types and stages of cancer (Zhang H et 
al.2008; Wang G et al 2008). Finally, a number of S100 proteins have been shown to 
interact with and to regulate various proteins involved in cancer and exert different effects 
on p53 activity (van Dieck J et al. 2009). 
S100 PROTEINS 
 
The S100 genes were among the first genes detected as differentially expressed between 
normal breast and breast cancer cells (Barraclough R and Rudland PS, 1994), or between 
different stages of breast cancer (Emberley ED et al.2004), that show the characteristics of 
possible biomarker for breast cancer. These proteins, identified by B.W. Moore in 1965, 
are called S100 because of their solubility in a 100%-saturated solution with ammonium 
sulphate at neutral pH (Moore BW, 1965). The S100 proteins are small, acidic proteins of 
10 and 12 kDa, found exclusively in vertebrates (Donato R, 2003). The S100 proteins are a 
multi-gene calcium-binding family comprising 20 known human members each coded by a 
separate gene. Many S100 proteins are located on chromosome 1q21, in the so-called 
epidermal differentiation cluster (Marenholz I et al, 2004; Schafer BW et al.1995).  
 
Structure of S100 proteins 
S100 protein are characterized by the presence of two Ca
2+
 binding motifs of the EF-hand 
type interconnected by an intermediate region often referred to as the hinge region. In each 
Ca
2+
 binding motif of the EF-hand type, a Ca
2+
-binding loop is flanked by α-helices, 
resulting in a helix-loop-helix arrangement. Thus, helices I and II flank loop 1 and helices 
III and IV flank loop 2 (Salama I.et al. 2008) (figure 7). 
 
 
Figure 7: Scheme showing the structure of the protein S100. 
 
In the case of S100 proteins, the first Ca
2+
-binding loop is unconventional, in that it is 
longer and rearranged, whereas the second Ca
2+
- binding loop is canonical. Hence, the two 
Ca
2+
- binding sites in an S100 protein bind Ca
2+
 with different affinities, a higher affinity 
in the case of the C-terminal site and a much lower affinity in the case of the N-terminal 
site (Donato R, 2001). 
The second Ca2+-binding site is followed by a C-terminal extension. As expected, the 
highest sequence identity among S100 members is found in the Ca2+-binding sites. 
Instead, the hinge region and the C-terminal extension display the least amount of 
sequence identity, suggesting the possibility that these two regions might have a role in the 
specification of the biological activity of individual S100 proteins  (Hilt DC and Kligman 
D, 1991). 
The S100 proteins have the ability to form homodimers, heterodimers and oligomers. In 
general, however, S100 proteins are suggested to function as Ca
2+
 sensor proteins that 
undergo Ca
2+
-dependent conformational changes. These latter result in the exposure of a 
binding surface through which S100 proteins interact with target proteins. (Donato R,1999) 
(figure 8) 
 
Figure 8: Three-dimensional structure of S100 proteins and model of interaction with target proteins. 
 
 
 
 
Functions of S100 proteins 
It is well documented that S100 proteins have a broad range of intracellular and 
extracellular functions [Donato R, 2001; Donato R, 2003 ]. Intracellular functions include 
regulation of protein phosphorylation and enzyme activity, calcium homeostasis, 
regulation of cytoskeletal components and regulation of transcriptional factors. When they 
are present extracellularly, they act in a cytokine like manner through the receptor for 
advanced glycation endproduct (RAGE) (Leclerc E et al. 2009). In particular some 
members of this family act as leukocyte chemoattractants, macrophage activators and 
modulators of cell proliferation (Hiratsuka S et al. 2006). These functions associate S100 
proteins with a variety of pathologies such as inflammation and cardiomyopathies, and 
gradually their role in carcinogenesis is beginning to unravel.  
 
S100 proteins and tumor 
It is clear that some S100 proteins act as tumour promoters and others as tumour 
suppressors, and there is tissue specificity in their actions. Moreover a number of S100 
proteins interact with p53 and can exert different effects on p53 activity (Mueller A et al. 
2005; Grigorian M et al. 2001). 
The tumour suppressor p53 is a crucial factor in the development of cancer. It acts as the 
central inducer of apoptosis and cell cycle arrest (Levine AJ 1997; Vousden KH 2000). Its 
activity is regulated by posttranslational modifications and interaction with other proteins 
(Appella E et al. 2000; Braithwaite AW et al. 2006; Lavin MF and Gueven N, 2006). 
Both S100A4 and S100B are thought to inhibit p53 phosphorylation leading to inhibition 
of its transcriptional activity, thereby compromising p53 tumour-suppressor activity 
(Grigorian M et al. 2001). In contrast S100A2 promotes p53 transcriptional activity and 
interestingly S100A4 has also been documented as enhancing p53-dependent apoptosis. 
Thus the balance of actions of different S100 proteins within a cell will determine P53 
function. Many of the S100 family members have a role in modulating cytoskeletal 
dynamics. Again they display remarkable diversity of function, exhibiting direct 
interaction with tubulins, intermediate filaments, actin, myosin and tropomyosin 
(Santamaria-Kisiel L et al.2006). Some of these processes have been implicated in 
mediating metastasis. A number of members of the S100 family have also been shown to 
play a role in modulating proliferation, while both S100A1 and S100A11 shown to inhibit 
cell proliferation (Kriajevska M et al.1998). 
 
 
S100A2 
S100A2 protein was identified as tumor suppressor gene by subtractive hybridization 
between normal and tumor derived human mammary epithelial cells (Lee S et al. 1991). 
S100A2 gene is markedly down-regulated in several tumor tissues of various origins like 
melanomas (Maelandsmo G. et al. 1997) and breast carcinoma (Pedrocchi M et al. 1994). 
Repression of gene expression in tumor cells depended by site-specific DNA methylation 
of the S100A2 gene promoter (Wicki, R et al. 1996). Moreover, several growth factors 
were reported to alter the S100A2 gene expression at late G1/S-phase, indicating that 
S100A2 is cell cycle-regulated (Lee S et al.1992). Much attention has been paid to the 
expression of the S100A2 gene and gene product in head and neck squamous cell 
carcinoma (HNSCC), where is overexpressed (Nagy N et al 2001; Lauriola L et al. 2000).  
 
 
 
 
S100A3 
S100A3 binds Ca
2+
 with poor affinity but Zn
2+
 with exceptionally high affinity. This high 
affinity for Zn
2+
 is attributed to the unusual high Cys content of S100A3. The protein is 
highly expressed in fast proliferating hair root cells and astrocytoma pointing toward a 
function in cell cycle control. (Gunter F et al. 2002). 
Previous studies suggest a close association of S100A3 with epithelial differentiation, 
leading to hair shaft formation, but its molecular function is still unknown. 
 
 
S100A4 
S100A4, also named metastasin, is a small molecule and can pass through the nuclear 
pores without any active transport mechanism being involved. S100A4 binds and inhibits 
phosphorylation of the p53 C-terminal peptide by protein kinase C. The tumor suppressor 
protein p53 has also been identified as an S100A4 interacting protein and may provide a 
link between S100A4 and apoptosis (Lombet A et al. 2003).  
S100A4 is involved in several aspects of tumor progression including motility, invasion, 
metastasis and apoptosis (Takenaga K et al. 1994; Ambartsumain N et al.2001) (figure 9). 
The molecular mechanisms by which S100A4 exerts these functions remain unclear, and 
considerable functional diversity is created by the fact that extracellular, intracellular, 
tumor-derived, and stroma-derived S100A4 all contribute to metastatic dissemination. 
Intriguingly, S100A4-mediated induction of EMT may explain several of the prometastatic 
actions of S100A4 (Boye K and Maelandsmo GM, 2010). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It has also been reported that extracellular secreted S100A4 can affect cell differentiation 
and migration (Belot N et al. 2002). Numerous studies have investigated the potential use 
of S100A4 as a prognostic marker. An increase in S100A4 protein expression has been 
correlated with a worse prognosis for patients with different types of cancer including 
Figure 9: Mechanisms involved in S100A4-mediated metastatic progression. A: Molecular mechanisms 
associated with intracellular functions of S100A4. S100A4 interact with cytoskeletal proteins, 
particularly nonmuscle myosin heavy chain (NMMHC) IIA, and increase cell migration. Intracellular 
S100A4 expression is also associated with transcriptional regulation of certain genes, such as MMPs and 
E-cadherin, through so far unidentified mechanisms. B: Molecular mechanisms associated with 
extracellular S100A4. S100A4 is released from both tumor cells and stromal cells. Through interaction 
with annexin II (AII) and tissue plasminogen activator (tPA) on the surface of endothelial cells, S100A4 
stimulates the conversion of plasminogen to plasmin, thus promoting angiogenesis. S100A4 also 
interacts with other cell surface receptors on both tumor cells and stromal, such as RAGE, to activate 
intracellular signal transduction cascades, including mitogen-activated protein kinases, increased 
intracellular [Ca
2+
], and nuclear factor-κB. S100A4-activated signaling pathways may, in turn, result in 
regulation of several target genes probably involved in stimulation of metastasis. C: Biological 
processes associated with S100A4. S100A4 stimulates cell motility, invasion, and angiogenesis and 
participates in the regulation of cell death. Invasion and motility is probably promoted through induction 
of EMT. Cell motility, invasion, and angiogenesis all contribute to stimulation of metastasis. 
colorectal, gallbladder, bladder, esophageal, breast, and non small lung cancer (Gongoll S 
et al. 2002). 
 
 
S100A6 
The S100A6 protein (calcyclin), similarly to other members of the S100 protein family, 
forms homodimers in solution in a Ca2+- independent manner (Wojda U and Kuźnicki J 
1994; Potts BC et al. 1995). In addition, S100A6 may form a covalent dimer through a 
disulfide bridge between cysteine residues at position 2.  
S100A6 is predominantly a cytoplasmic protein but in the presence of Ca
2+
 it associates 
with the plasma membrane and the nuclear envelope (Stradal TB and Gimona M, 1999), 
possibly as a result of its interaction with membrane-bound proteins. S100A6 expression at 
the protein and/or mRNA level can be upregulated by multiple factors including platelet-
derived growth factor (PDGF), epidermal growth factor (EGF), tumor necrosis factor 
(TNFa) (Tsoporis JN et al. 2008), retinoic acid (Tonini GP et al. 1991), estrogen (Hong EJ 
et al. 2006). S100A6 level also increases upon stress conditions such as ischemia 
(Lewington AJ et al. 1997), irradiation (Orre LM et al. 2007) or oxidative stress (Lesniak 
W et al. 2005). 
Several early reports prompted the investigation of a potential role of S100A6 in the 
development of malignancy. For instance, high S100A6 mRNA levels were found in 
peripheral blood cells from patients with chronic myelogenous leukemia and in some 
human breast cancer cell lines. 
Owing to alternations of the S100A6 expression level during cancer progression the 
S100A6 protein was recognized as a useful diagnostic tool for defining cancer stage and 
discriminating between various cancer types as in the case of cholangio carcinoma and 
hepatocellular carcinoma (Kim J et al. 2002). Furthermore, differences in S100A6 level 
can be useful for the discrimination between primary liver tumors such as hepatocellular 
carcinoma and metastases derived from colorectal carcinoma (Melle C et al. 2008). 
 
 
S100A7 
Psoriasin (S100A7) was originally identified as one of the most abundant proteins in 
psoriatic keratinocytes (Madsen P et al. 1999). Subsequent studies showed that psoriasin 
expression is up-regulated in abnormally differentiating keratinocytes, squamous 
carcinomas of different organs, and in a subset of breast tumors (Alowami S et al. 2003; 
Emberley ED et al. 2004). Psoriasin was identified as one of the few genes that is highly 
and more frequently expressed in ductal carcinoma in situ (DCIS) than in invasive breast 
carcinomas, suggesting a potential role in tumor progression. In human invasive breast 
carcinomas, the expression of psoriasin has been shown to correlate with unfavourable 
histopathologic features, including estrogen receptor (ER) negativity and poor clinical 
outcome (Enerback C et al. 2002; Porter D et al. 2003 ). Psoriasin protein was found to be 
secreted but also present in the cytoplasm and the nucleus of cells expressing it. Psoriasin 
was found to interact with Jab1 (figure 10), a component of the COP9 signalosome that is 
involved in multiple signal transduction pathways, including the regulation of E3 ubiquitin 
ligases and the JUN/AP1 transcription factors. Overexpression of psoriasin in MDA-MB-
231 breast cancer cells was shown to influence the intracellular distribution and activity of 
Jab1 and enhance tumorigenesis and metastasis (Emberley ED et al. 2003). 
  
 
 
 
 
 
 
 
 
S100A8-S100A9 
S100A8 and S100A9 are released from activated phagocytes and exerts antimicrobial 
activity as well as cytotoxicity against various tumour cells (Ghavami S et al. 2004). They 
are differentially expressed in a wide variety of cell types and are abundant in myeloid 
cells. High expression of S100A8 and S100A9 has been reported in disorders such as 
rheumatoid arthritis, inflammatory bowel disease and vasculitis (Nacken W et al. 2003). 
The interaction with RAGE represent a novel proinflammatory axis involved in several 
inflammatory diseases. Evidence has accumulated that S100A8/A9 induces cell death 
Figure 10: The influence of S100A7 on the prosurvival and proinvasive pathways is mediated through 
alterations in gene expression. The interaction of S100A7 with c-jun activation domain binding protein 
1 (Jab1) results in a cellular redistribution of Jab1 to become predominately localized in the nucleus, 
where it stimulates gene transcription. Jab1acts as a cofactor to stimulate transcription of genes 
regulated by the NF-κB, activator protein- 1 and HIF1 transcription factors. Extracellular S100A7 may 
also interact with the receptor of advanced glycation of end products (RAGE) receptor, resulting in 
activation of signal transduction cascades and, ultimately, activation of gene transcription. S100A7 is 
believed to exert its effects through Jab1 and other proteins with which it forms an interaction, and one 
outcome is an alteration in gene transcription. 
through a dual mechanism: one associated with zinc extraction from the target cells, the 
other through binding to the target cell surface, possibly via ligand-induced receptor 
activation (Kerkhoff C et al. 1998).  
 
 
S100A11 
In several studies, S100A11 was shown to be up- or down-regulated in different tumor 
entities (Melle C et al. 2006). S100A11 plays a dual role in growth regulation of human 
keratinocytes: inhibit the Ca2+- induced cell growth and stimulate the cell growth 
enhancement of the level of EGF protein family members (Sakaguchi M et al. 2003; 
Sakaguchi M et al. 2008). S100A11 through a p53 independent mechanism is able to 
mediate the stimulation of the activity of the 
cell cycle regulator p21
WAF1/CIP1 
during cellular 
stress stimuli such as increase of extracellular 
Ca
2+
 concentration as well as induction of DNA 
damage (Murzik U et al. 2008). In particular, 
S100A11 by nucleolin-mediated translocation 
into the nucleus regulate p21 transcription 
(Figure 11). 
 
 
 
Nucleolin was described as a shuttling protein which is involved in directed translocation 
into the nucleus of several proteins (Stepanova V et al. 2008; Jerke U et al. 2009). 
Figure 11: schematic representation of the 
interaction between nucleolin and S100A11; 
the complex translocate into the nucleus and 
regulate the p21 transcription. 
It is also demonstrated that the accumulation of S100A11 in nuclei was more effective 
after DNA damage compared to the Ca
2+
 stimulus.  
 
 
S100A12 
S100A12 (EN-RAGE, Calgranulin C) is a members of the S100/calgranulin family such as 
S100A8 (MRP8, Calgranulin A) and S100A9 (MRP14, Calgranulin B).  
The role of S100A12 has been implicated in the innate immune system in response to 
infection. The exact nature of S100A12 ligand interaction is unclear, it has been shown 
able to bind both itself and a range of other molecules and was suggested to act as a 
molecular chaperone in the presence of calcium (Hatakeyama T et al. 2004). RAGE has 
been identified as a receptor for S100A12 (Hofmann MA et al. 1999). The RAGE 
interaction leads to initiation of pro-inflammatory signalling cascades via MAP-Kinase and 
NFkB, resulting in increased adhesion molecules expression (Yang Z et al. 2001). 
Increased serum concentration of S100A12 has been shown in patients with severe 
bacterial infections (Kim MH et al. 2006), and therefore used as diagnostic marker in 
inflammatory bowel disease (Foell D et al. 2003), arthritis (Foell D and Roth J, 2004) and 
asthma (Yang Z et al. 2007). Moreover, S100A12 interaction with RAGE is able to 
activate endothelial, lymphocyte and macrophage cells directly (Roth J et al. 2003).  
 
 
S100A13 
Although S100A13 is similar to most S100 family members in that its homodimers possess 
two high- and low-affinity Ca
2+
 binding sites, it does not exhibit a calcium dependent 
exposure of the hydrophobic surface which is important for the interaction of other S100 
proteins with their target peptides (Ridinger K et al. 2000). This protein has since been 
found to play a crucial role in the release of FGF-1 (Mouta Carreira C et al. 1998). The 
FGF family is known to be involved in angiogenesis (Presta M et al. 2005) and tumour 
metastasis and the growth is dependent upon tumour angiogenesis in vivo (Folkman J and 
Shing Y, 1992) Indeed, it is possible that S100 gene family members, including S100A13, 
support neoplastic and pro-inflammatory situations in vivo by their ability to participate in 
the release pathway for angiogenic and inflammatory signals such as FGF-1 and IL-1a 
(Mandinova A et al. 2003). S100A13 is widely expressed in many types of tissues, with 
particularly high expression in the thyroid gland. The localisation of S100A13 expression 
in human smooth muscle cells differs from that of all other S100 proteins. S100A13 is 
expressed in the perinuclear area of these cells, which suggests diverse functions for 
S100A13 in signal transduction (Ridinger K et al. 2000). 
 
 
S100A15 
The highly homologous human S100A15 (hS100A15) was recently identified in psoriasis 
and found to also be upregulated in lesional skin (Wolf et al. 2003). Genomic analysis of 
the S100A7 and S100A15 encoding chromosomal regions reveals that both must have 
evolved by gene duplications during primate evolution, forming an innate subfamily in 
man (Kulski et al. 2003). 
The co-expression of the hS100A7 and hS100A15 in psoriasis suggests that both proteins 
participate in keratinocyte maturation, proliferation and/or skin inflammation. However, 
the existence of two highly similar paralogs (>90% identity) sets certain limits in 
discriminating between them when co-regulated. Furthermore, little is known about the 
functional role of the S100A7/A15 proteins in cutaneous pathology, yet they are frequently 
dysregulated in a variety of pathological conditions including cutaneous cancer. 
  
AIM OF THIS STUDY 
 
Breast cancer is still one of the leading causes of cancer death in women. Indeed, it 
consists of several different subtypes with different molecular profiles, biological 
behaviour, and risk profiles. Current clinical parameters with prognostic and predictive 
factors constitute important tools for the identification of breast cancer therapy providing 
an efficient treatment. However, these parameters remain inadequate for appropriate 
stratification of patients, given that more than 1% of all human genes are implicated via 
mutation in cancer. Proteomic screening for differential protein expression in tumor 
samples represents a fundamental tool to understand biological pathways involved in 
breast cancer. In addition, it could be useful for the identification of biomarkers also in 
early detection of cancer. Moreover immunoproteomics, that defines the subset of proteins 
involved in the immune response, hold considerable promise for the discovery of tumor-
associated antigens (TAAs) and autoantibodies targeting specific tumor-associated 
antigens as potential group of serum biomarkers in early cancer diagnosis. 
Preliminary study performed in our laboratory demonstrates quantitative and qualitative 
differences in the proteomic profiles between ductal infiltrating breast cancer tissues and 
the non-tumoral adjacent counterparts. Subsequently, from the analysis of comparative 
proteomic profiles of breast cancer tissues, it has been shown that a large proportion of the 
tumor-derived proteins are present in all patients, including glycolytic enzymes, detox and 
heat shock proteins, and calcium binding proteins; conversely some proteins, including 
psoriasin (S100A7), cofilin1 and galectin, showed sporadic and high expression level, 
which suggest their possible role for patients stratification (Pucci-Minafra I et al. 2007). In 
particular, a group of proteins that has emerged as potentially important markers in 
multiple types of cancer is the S100 family. The altered expression of S100 family 
members was demonstrated in several types of cancer (breast, lung, bladder, kidney, 
thyroid, stomach and prostate) and in general the overexpression of these proteins is 
associated with tumor progression.  
Although the knowledge about cancer biomarkers is increasing enormously in the last 
years, however much still remains to be comprehend for a better stratification of patients 
and to improve the management of cancer patients by enhancing the efficiency of detection 
and efficacy of treatment.  
In order to identify new protein clusters involved in breast cancer progression and to find 
potential diagnostic, prognostic and therapeutic biomarkers, the present study aims to: 
 Expand the number of breast cancer tissues analysed, increasing the number of 
identified proteins and find new functional pathways involved in breast cancer 
progression. 
 Extended the research to S100 proteins family that are potentially involved in 
tumor progression. 
 Identify circulating antibodies direct against specific tumor antigens as putative 
biomarker through SERPA approach. 
 
  
PRELIMINARY DATA 
 
Preliminary study performed in our laboratory demonstrates quantitative and qualitative 
differences in the proteomic profiles between ductal infiltrating breast cancer tissues and 
the non-tumoral adjacent counterparts of 13 pairs of surgical samples (figure 12). Tumor 
tissues showed a greater abundance of cellular proteins compared with normal 
counterparts, enriched instead in extracellular amount (Pucci-Minafra et al. 2007). The 
healthy tissue of adult women mammary gland contain a reduce amount of parenchyma 
with respect to the tumor mass. 
 
Figure 12: Panel showing the miniatures of the 2-D matching maps from 13 surgical specimens of BCT and 
its NAT. 
 
In figure 12, 13 proteomic maps of breast cancer tissue and their adjacent healthy 
counterparts are shown. These maps have been analysed with Image Master 2D Platinum 
and compared for differentially expressed proteins. These were grouped based on the 
closest affinity for their major biological functions in: 1) cytoskeleton and associated 
proteins; 2) metabolic enzymes; 3) molecular chaperones; 4) proliferation and 
differentiation regulators; 5) detoxification and redox proteins; 6) protein degradation; 7) 
serum proteins.  
Subsequently, proteomic profiles from 37 breast cancer surgical tissues, with ductal 
infiltrating diagnosis, were compared for proteomic screening of differential expression 
proteins. This approach indeed may contribute to the knowledge of biological pathways 
and allow a molecular classification of cancer for patients stratification and biomarkers 
discovery (Pucci-Minafra et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Panel showing an experimental window from ImageMaster 2D Platinum software containing the 
sections of actin spots (white crosses) from the matched two-dimensional gels of the 37 breast cancer surgical 
tissues. 
P01 P02 P03 P04 P05
P07 P08 P09 P10
P11 P12 P13 P14 P15
P16 P17 P18 P19 P20
P21 P22 P23 P24 P25
P26 P27 P28 P29 P30
P31 P32 P33 P34 P35
P36 P37
P06
In this study, since proteomic profiling may be influenced by extension and amount of 
neoplastic cells within the host stroma, an objective criterion to compare proteomes of 
different tissues has been introduced: the expression levels of individual proteins have been 
normalized for actin content. Figure 13 shows cropped windows containing the actin spot 
from 37 2D-gels, attesting the variability of actin amount among different tissues, most 
likely as an effect of different cellularity (that is, cell densities within an area of the 
surgical sample), in the examined samples, under the same quantity of protein loading in 
the 2D-IPG. 
Analysing the distribution of the identified protein among the group of 37 breast cancer 
tissues, it is clear that some proteins are ubiquitously present in all examined tissues, 
whereas others appear sporadically. Among the sporadic one, some proteins when present, 
showed high expression levels. For instance Psoriasin (S100A7) is one of the most variable 
proteins among the 37 patients. It is highly expressed in 15/37 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
In order to identified novel protein clusters in breast cancer tissues potentially involved in 
tumor progression, the first part of my thesis regarded the enlargement of previous cohort. 
Indeed the number of processed and studied samples was increased, up to 100 breast 
cancer tissues as shown by miniature of the 2D gels (figure 14). 
 
Figure 14: miniature of 100 2D gels from ductal infiltrating breast cancer tissues. 
The proteomic expression profiles among 2D gels resulted comparable, even if was evident 
the heterogeneity of protein expression levels among different tumoral tissue, under the 
same quantity of proteins loaded in 2D-IPG, due to a different content in cellularity of 
tumor mass. 
The number of identified proteins, was also enhanced through mass spectrometry and/or 
N-terminal sequencing, as describe in MM, identifying 213 protein spots corresponding to 
133 genes.  
 
Figure 15: prototype of a proteomic map of breast tumor tissue, used as reference map in this study. It shows 
the protein species identified by the access number of the Swiss-Prot/TrEMBL database.  
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In order to rationalize our data and to find functional pathways in which the identified 
proteins are involved, a gene ontology approach has been used. To this aim DAVID 
(Database for Annotation, Visualization and Integrated Discovery) Bioinformatics 
Resources, has been utilized as an excellent tool to provide functional interpretation of 
large lists of genes derived from genomic and proteomic studies. The program recognizes 
gene lists and displays results in terms of significance, correlating to each group of genes 
two values that are Fisher exact P-value index and Benjamini FDR: False Discovery Rate. 
The first is a variant of the p-value that indicates whether the association of a gene in a 
given cluster is reliable or due to chance; the second parameter of significance is 
Benjamini, who represents the percentage of false positives that you would expect from a 
list of genes that DAVID has grouped in the same cluster. 
The gene list corresponding to the 213 proteins was uploaded into DAVID Bioinformatics 
database that identified, with a certain degree of significance, the molecular pathways in 
which these proteins are involved, by clustering them in functional classes. The application 
of the powerful Bioinformatics Resources for gene/protein classification provided by 
DAVID knowledgebase, while confirming our previous protein classification, introduced 
new terms for further remodulation of protein clusters on the basis of the multiple 
functions for individual proteins. In particular we found a high number of proteins with 
specific biochemical functions, converging towards common pathways. Overall, three 
predominant pathways the gene cluster of regulation of programmed cell death, comprising 
23 genes, cell motility cluster, comprising 17 genes, and glycolysis, comprising 11 genes, 
were at first places for robustness (figure 16). It is known, that proteins belonging to these 
clusters are involved in different biological processes and play different cellular functions 
but may be deregulated during cancer progression. 
 Figure 16: functional cluster of identified protein obtained through DAVID Bioinformatics Resource. 
 
Regulation of programmed cell death  
The processes related to programmed cell death are essential for turnover of cells in organs 
and tissues, as well as to remove cells whose genome would be irretrievably altered by 
chemical, physical and environmental factors. The alteration of expression and activity of 
proteins belonging to this cluster may cause an imbalance between pro-apoptotic and anti-
apoptotic stimuli, leading to a neoplastic transformation.  
The genes corresponding to the identified proteins belonging to this cluster were: CALR, 2 
isoforms of ANXA1, ANXA5, 3 isoforms of COF1, DDAH2, GDIR, GRP94, GSTPI, 5 
isoforms of HSP27 , 2 isoforms of HSP60, 2 isoforms of LEG1, MIF, NDKA, NDKB, 
NPM a, 2 isoform of PDIA3, PHB, 3 isoforms of PRDX2, PSA5, SODC, SODM, TCTP, 2 
isoforms of TERA. About the 50% of the genes belonging to this category, codify for 
proteins with anti-apoptotic functions. The cluster of anti-apoptotic proteins, corresponding 
to 12 genes was compared among the 100 proteomics maps and the 13 reference non-
tumoral tissue maps. The comparative proteomic profiling showed: 1) a highly significant 
overexpression of several members of the anti-apoptotic protein cluster in the cancer 
tissues vs non tumoral counterparts; 2) a relative variability of the expression levels of the 
normalized proteins within patients. The distribution among the whole group of 100 
patients of the cell death cluster was significantly high, with an average of 90% of protein 
expression (figure 17). The general expression pattern of proteins involved in anti-
apoptotic pathways confirms the cell survival-dependence for primary tumor growth. 
 
Figure 17: The regulation of programmed cell death graph show for each patients, the distribution of clusters 
that express. 
 
Among proteins of this category reaching the high levels of expression, we observed: 
nucleophosmin (NPM), a crucial regulator of p53; translationally-controlled tumor protein 
(TCTP1), a protein involved in calcium binding and microtubule stabilization; cofilin 
(COF1), an actin-binding protein responsible also for the signal translocation from 
cytoplasm to nucleus; annexin A1 (ANXA1) a calcium/phospholipid-binding protein which 
promotes membrane fusion and ruffling, glutathione s-transferase (GSTP1), which plays 
important roles in detoxification but having also a role in susceptibility to cancer; heat 
shock protein 27 (Hsp27) that regulates apoptosis through its ability to interact with key 
components of the apoptotic-signaling pathways, particularly those involved in caspase 
activation; peroxiredoxin 1 (Prx I) regulates cell proliferation and apoptosis by its 
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interaction with oncogene products such as c-Abl; NDKA also named nm23-H1 plays 
complex roles in the development of diverse cancers including breast carcinoma, high-
grade lymphomas, and acute myeloid leukemia (AML). High levels of nm23 gene 
expression has been noted in the advanced stage of thyroid carcinomas and associated with 
significant reductions in survival for neuroblastoma and osteosarcoma patients. 
 
Cell motion  
Cancer cells usually undergo to profound remodelling during neoplastic transformation, 
and this lead to acquisition and manifestation of the invasive phenotype of tumor cells. 
Among the proteins belonging to cell motility cluster there are ACTB, ANXA1, ANXA1 a, 
COF1 b, COF1 c, COF1 d, GDIR, GDIS, HSP27 a, HSP27 b, HSP27 c, HSP27 d, HSP27 
e, VIME a, VIME b, VIME c, VIME d, VIME fr, VINC a, VINC b several of them are 
implicated in different diseases, such as: the actin binding protein called Cofilin is involved 
in the invasive and metastatic phenotype of tumour cells (Wang W et al. 2007). In many 
cell types, the formation of membrane protrusions and directional migration depend on the 
spatial and temporal regulation of this protein; Annexin A1 (AnxA1) is a candidate 
regulator of the epithelial- to mesenchymal (EMT)-like phenotypic switch, a pivotal event 
in breast cancer progression. AnxA1 promotes metastasis formation by enhancing 
TGFbeta/Smad signalling and actin reorganization, which facilitates an EMT-like switch, 
thereby allowing efficient cell migration and invasion of metastatic breast cancer cells (de 
Graauw M et al. 2010); Vimentin is one of the cytoplasmic intermediate filament proteins 
which are the major component of the cytoskeleton. Elevated vimentin expression level 
well correlates with up-regulated migration and invasion of cancer cells (Gilles C et al. 
2003). 
 
  
Figure 18: The cell motion graph show for each patients, the distribution of clusters that express. 
 
The distribution of the cell motility cluster was significantly lower rather the regulation of 
programmed cell death cluster and dissimilar among patients, with an average of 70% of 
protein expression among patients (figure 18). 
The more irregular expression of proteins involved in cell motility, clearly demonstrated 
the heterogeneity of metastatic potentialities among patients and suggests the possibility of 
using some of the motility cluster proteins as prognostic factors for metastasis propensity. 
 
Glycolysis  
Cancer cells alter their metabolism in order to support their rapid proliferation. Glucose 
deprivation can activate oncogenes and these can upregulate proteins involved in aerobic 
glycolysis. In turn, proteins implicated in increased glycolysis make tumor cells more 
resistant to apoptosis. Aerobic glycolysis induces acidification of the tumor environment, 
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by favouring the development of a more aggressive and invasive phenotype (Annibaldi A 
and Widmann C, 2010). It is well established that the process of cancer development and 
growth involves major alterations of cells‘ metabolism, leading to increase of proteins 
levels involved in this process. 
 
 
Figure 19: The glycolysis graph show for each patients, the distribution of clusters that express. 
 
This cluster contain 2 isoforms of ALDOA, 4 isoforms of ENOA, 2 isoforms fragment of 
ENOA, ENOG, 5 isoforms of G3P, 2 isoforms of KPYM, LDHA, LDHB, MDHC, 2 
isoforms of PGAM1, 3 isoforms of PGK 1, 4 isoforms of TPIS.  
The distribution of protein belonging to glycolysis cluster among patients, is quite high, 
with an average of almost 95% of protein expression (figure 19). Among the glycolytic 
enzymes, some of them have different roles: α-enolase for example, acts also a 
plasminogen receptor (Redlitz A et al. 1995) and thus mediates activation of plasmin and 
extracellular matrix degradation. In tumor cells α-enolase is up-regulated and supports 
anaerobic proliferation (Warburg effect), it is expressed at the cell surface, where it 
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promotes cancer invasion, and is subjected to a specific array of post-translational 
modifications, namely acetylation, methylation and phosphorylation. Both α-enolase 
overexpression and its post-translational modifications could be of diagnostic and 
prognostic value in cancer; GAPDH recently is described as a regulator of cell death; 
whereas some studies point toward a proapoptotic function, others describe a protective 
role and suggest its participation in tumor progression. 
  
RESULTS II 
Since S100 family can be consider as a potentially promising group of markers in cancer 
development and progression, we extended our research to identified other member of 
S100 proteins family also because, as described in our preliminary data, are expressed 
sporadically and with high level in breast cancer tissues (Pucci-Minafra et al., 2008).  
 
Proteomic screening for S100 members identification  
In this study is shown, for the first time, a large-scale proteomic investigation on breast 
cancer patients for the screening of multiple forms of S100 protein.  
Figure 20 shows the region covering a pI/kDa range of 4.5-7/15-9 kDa of a breast cancer 
tissue reference map, in which the majority of the S100 proteins are expected to localize. 
After a comprehensive mass-screening of protein spots included in this area, in different 
proteomic maps, we identified by MALDI-TOF the following S100 protein members: 
S100A2 (protein S-100L), S100A4 (metastasin), S100A6 (Calcyclin, Prolactin receptor-
associated protein), two isoforms, S100A7 (psoriasin), two isoforms, S100A8 
(Calgranulin-A), S100A11 (Calgizzarin), three isoforms and S100A13 (S100 calcium-
binding protein A13). A protein number appeared as multiple spots on 2-D gels, 
corresponding to isoforms of the same protein, possibly after post-translational 
modifications. 
 
 
 
 
 
Figure 20: region of 2D gel covering a pI/kDa range of 4.5-7/15-9 kDa where localize the majority of S100 
proteins 
Comparative proteomic analysis of S100 proteins between breast cancer tissues and 
normal adjacent tissues 
Comparative proteomic analysis performed in a pilot group of 10 patients showed the high 
significant expression of S100 members in the cancer tissues vs non tumoral counterparts.  
As shown in cropped windows of 2D gels, the S100 proteins are almost exclusive 
expressed in tumor tissues compared to adjacent healthy counterparts, even though the 
expression of some members (for example S100A2, S100A4, S100A7a and S100A8) is 
very low also in the tumor tissue (figure 21 A). The quantitative analysis of S100 protein 
expression level between breast cancer and normal adjacent tissues, performed by Image-
Master software as described in MM, showed significant differences for all S100 protein 
members (figure 21 B), except for S100A4 (expressed only in 5 patients) and for S100A6 
(expressed also in normal tissues). 
 
A
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Figure 21: A. Panel of cropped areas of individual S100 protein spots from matched breast cancer tissues 
(BCT) and non-tumoral adjacent tissue (NAT). B. Quantitative analysis of S100 proteins, given as boxplot 
graphs, of matched breast cancer tissues (BCT) and non tumoral adjacent tissues (NAT). 
 
The differential expression of S100 proteins was also confirmed by western blotting on 
three different patients for each S100 proteins(figure 22). 
 
 
Figure 22: Panel of Western Blot reaction of S100 antibodies, performed on three selected breast cancer 
tissues and their non tumoral counterpart. 
 
 
Occurrence of S100 proteins in a large sample-set of breast cancer patients 
We performed quali/quantitative proteomic screening in a cohort of 100 patients. 
Qualitative analysis (presence-absence) showed that some proteins are expressed in almost 
all patients (S100A6, S100A11, S100A2 and S100A13), while others are expressed in a 
variable number of patients, i.e.: S100A8 in 71% of the patients, S100A4 in 57% and 
S100A7 in 51% (isoform a) and 63% (isoform b) (figure 23 A). The quantitative 
evaluation showed that the expression levels of each S100 member was quite different 
from one to the others and among patients (figure 23 B), but collectively, most of the S100 
protein forms were statistically correlated to each others. This adds complexity to the role 
of this protein category in the breast cancer and suggests possible common pathway of 
(dys-)regulation.  
 
Figure 23: A. Qualitative analysis, table reporting the percentage of different S100 proteins among 100 
patients. B. Quantitative analysis, diagram of the relative intensities of the eleven S100 protein forms among 
100 patients, in abscissa are indicate the protein name and in ordinate the density values. 
 
 
Prognostic value of S100 proteins in breast cancer 
In order to investigate the prognostic value of S100 proteins to predict metastatic relapse 
during a time lapse of three years from the surgical intervention, patients were grouped 
into metastatic and disease free patients. Patients with 3-year follow-up were 57: 22 had 
developed distant metastases while 35 were disease-free. The expression level of each 
S100 protein (expressed as average among patients of each group) was higher in the 
metastatic group compared to disease free-group. The most robust correlation with 
metastases (calculated by unpaired F-test statistical method) regarded primarily, the protein 
S100A4 also named Metastasin for its presumed role in metastases promotion. Indeed, in 
different studies, S100A4 protein is involved in certain types of cancer (such as breast 
cancer, bladder cancer and lung adenocarcinomas) suggesting that S100A4 may play a role 
in cancer progression (Ismail NI et al. 2008; Agerbaek M et al.2006; Matsubara D et al. 
2005). Also in our analysis, S100A4 expression level shows an increase of more than 2 
fold in the metastatic group. 
Surprisingly the second most robust correlation involved with metastases is the protein 
S100A7 (S100A7a isoform), also named Psoriasin that was identified as highly expressed 
in psoriatic keratinocytes and is also highly and more frequently expressed in ductal 
carcinoma in situ (DCIS) (Krop I et al. 2005), thus suggesting a possible role in early 
stages of breast tumor progression in association with the development of the invasive 
phenotype. 
 
Western blot validation of S100A7 expression 
In agreement with the last result, we extended our analyses regarding S100A7 expression 
in breast cancer patients. We firstly confirmed, by 2D- Western blot, the proteomic 
expression of two different isoforms of S100A7, the more acid one and the more intense 
and basic second one (figure 24). 
 
 
 
 
  
 
 
 
Figure 24: two different S100A7 isoform in silver stained (left) gel confirmed by 2D western blotting (right). 
 
Next we investigated the occurrence of the S100A7 isoforms among patients. Quantitative 
evaluation showed that the expression level of the acidic form is always low or very low 
(according to an arbitrary scale), while the other isoform is expressed at very high level in 
11% of patients (Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
Figure 25: quantitative evaluation of S100A7 isoforms in 100 breast cancer tissues. 
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The immunological validation of the S100A7 expression in the patients, performed by 
mono-dimensional WB, overlaps with the expression pattern of the S100A7 basic isoform 
in 2D gels, confirming also its sporadic expression (figure 26) 
 
 
Figure 26: 1D-western blotting on 100 breast cancer tissues performed with anti S100A7 antibody. 
 
 
The immunohistochemical evaluation on paraffin-embedded tissue sections for S100A7 on 
random selected breast cancer tissues showed that S100A7 expression, when present, is 
confined only to tumoral cells. S100A7 immunoreactivity was scored from moderate to 
strong in analyzed samples. Moreover, the expression of psoriasin was focal (≤ 10% of 
tumor cells) in some cases, heterogeneous (> 10 to < 75% of tumor cells) or marked (≥ 
75% of tumor cells) in other cases. All positive tumors showed cytoplasmic expression, 
and among these, nuclear expression of psoriasin was also observed (figure 27).  
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 Figure 27: immunohistochiemical evaluation of S100A7 in three different breast cancer tissues; below: 
enlarged view of the same tissues, in which is evident the nuclear localisation of the protein. 
 
 
Functional correlation of S100A7 and pathways analysis 
Finally, in order to investigate biochemical functions of S100A7 into the cells and 
understand the possible role in breast cancer progression, we performed proteomic 
correlation analysis with other proteins identified in the proteomic maps. The association 
was determined using Person correlation. A p value less than 0.05 was considered 
significant, a p value less than 0.01 was considered high significant and a p value less than 
0.001 very high significant. The expression of S100A7 proteins was positively correlated 
with 45 protein spots. In particular 20% of proteins were associated with the more acidic 
form of S10A7, while 80% showed correlation with the isoform b. (Table 2) 
 Table 2: Proteomic correlations analysis between S100A7 isoforms and proteins identified in breast cancer 
tissue map 
 
 
Since proteomic organisation into functional protein categories is fundamental to 
understand biochemical functions from a global point of view, the list corresponding to the 
AC in Swiss-prot of S100A7-correlated proteins was running into DAVID Bioinformatics 
database for functional clustering. The program found 4 different clusters for the S100A7 
correlated proteins. These are: calcium binding proteins, antiapoptotic proteins, antioxidant 
enzymes and glycolitic enzymes. This is an important result because represents the first 
link between S100A7 expression with these important pathways, correlated to cancer 
progression. The high correlation among S100A7 and calcium binding proteins such us 
S100A4 and S100A8/9 has previously described also by other authors (Zibert JR et al. 
2010; Liu H et al. 2007). 
 
Molecular classification of tumors for patient stratification 
In order to identify biologically and clinically significant subgroups of patients with a high 
risk of progression to invasive disease, the set of 45 S100A7 associated proteins were used 
to perform hierarchical clustering of patients based on Person correlation measure of the 
expression pattern and complete linkage. This revealed that the patients consistently 
separated into three major groups with distinguishable protein expression profiles.  
We analysed patients who underwent to cancer progression, and interestingly, the majority 
of the patients with tumor progression belonging to cluster 1, the 28% of the patients who 
underwent tumor progression are in the second cluster, while cluster 3 contain a smaller % 
of the patients with horse prognosis. So we can speculate that cluster 1 identify patients 
with high risk of progression, cluster 2 identify patients with moderate risk of progression 
and cluster 3 contain patients with low risk of tumor progression. 
  
RESULTS III 
 
Previously in my thesis, DAVID bioinformatics has been used to identify functional 
pathways involved in breast cancer such as glycolysis cluster that results among the 
clusters at first places for robustness. Indeed it is well known that transformed cells display 
increased levels of glycolytic enzyme mRNA and protein, that, can act as tumor associate 
antigens (TAA). If these antigens undergone post-translational modifications (PTMs), may 
be perceived as foreign by the immune system that is induced to product autoantibodies. 
The generated sera autoantibodies targeting TAAs could be useful as early molecular 
signatures for diagnostics and prognostics of cancer patients. 
Immunoproteomics, which defines the subset of proteins involved in the immune response, 
holds considerable promise for the discovery of tumor-associated antigens, suggesting that 
this approach may be a useful tool for identification of prognostic, diagnostic markers and 
novel therapeutic targets. Recently, various different approaches has been developed to 
identify autoantibodies against tumor-associated antigens from tumor patients' sera. 
In this study, in order to identify circulating antibodies direct against specific tumor 
antigens as putative biomarker, SERological Proteome Analysis (SERPA) was initially 
performed as preliminary study in breast cancer sera. 
Proteins lysate from breast cancer tissue were separated using 2D electrophoresis, 
transferred into a nitrocellulose membrane and incubated with immunoglobulins (Ig) 
purified from serum of the same patients that are used as primary antibodies. 
Immunoglobulin isolation from serum was conduct by immunoprecipitation technique, 
standardized in our laboratory, with protein A sepharose that binds specifically the Fc 
domain of Ig (as described in MM). 
 
 Figure 28: A Two-dimensional Western blot performed using the autologous serum purified by protein A; B 
correspondent silver stained breast cancer tissue. In red is indicated the region where the protein enolase 
migrates. 
 
Figure 28 A shows the outcome of 2D-western blot as described above. Through the 
matching with reference map of breast cancer tissue (figure 28 B) generated in our 
laboratory, we identified a large amount of immunoglobulin, but also a specific signals 
derived from different proteins, including putative acidic isoforms of α-enolase (in red 
box).  
Enolase was originally characterized as an enzyme involved in glycolytic metabolism. 
More recent evidence, however, shows that enolase is a multifunctional protein. In 
mammalian cells, three isoforms of enolase have been found. They are designated as a-
(ENO1), h-(ENO3), and g-(ENO2) 
enolases. The expression of these isoforms is developmentally regulated in a tissue-specific 
manner. ENO1 is widely distributed in a variety of tissues, whereas ENO2 and ENO3 are 
exclusively found in neuron/neuroendocrine and muscle tissues, respectively (Pancholi V 
2001). Enolases form heterodimers or homodimers to convert 2-phosphoglycerate into 
A B
phosphoenolpyruvate in glycolysis. In addition to its glycolytic function, as previously 
described in this thesis, ENO1 exist on the cell surface working as one of the plasminogen 
receptors and it may play a role in tissue invasion. In hypoxic conditions, it also acts as a 
stress protein that is up-regulated and speculated to provide protection to cells by 
increasing anaerobic metabolism (Jiang BH et al. 1997). By using an alternative translation 
start codon, ENO1 transcripts can be translated into a MBP1-like p37, which is localized to 
nucleus and binds to the c-myc P2 promoter (Feo S et al. 2000). 
 
 
Figure 29 : 2D IPG of  proteins extracted from tumor tissue and immunoprecipitated using protein A. In red 
is indicated the region where the protein enolase migrates. 
 
To validate further these data and to better comprehend if linkage between Ig and its ligand 
is specific, we performed tissues immunoprecipitation with corresponding sera Ig. At first 
protein A sepharose was incubated with serum to isolate Ig and then tissue lisate derived 
from the same patient, was added to isolate immunoprecipitated proteins. With this 
approach is possible to appreciate which tissue proteins are recognized from the enriched 
fraction Ig of the serum. Finally we separated the immunoprecipitated proteins by 2D 
electrophoresis and stained with silver nitrate. Also in this silver stained gel (figure 29) , 
among all the proteins detected, is possible to discriminate the putative acidic isoform of α-
enolase (in red box). 
To confirm the identity of these immunoreactive antigens, the spots were excised from 
breast cancer tissue (figure 30 A) and subjected to in-gel tryptic digestion and MALDI-
TOF mass spectrometry analyses. Figure 30 B shows the MS spectra obtained from these 
acidic isoform spots, confirming the enolase identities. This data was further confirmed by 
a 2D western blotting utilizing the purified antibody anti-enolase (Santa Cruz) on breast 
cancer tissue. (figure 30 C) 
 
 Figure 30: A Identification of immunoreactive spots present in a parallel gel stained with blue comassie B α 
Enolase by MALDI-TOF C by two-dimensional Western blot. 
 
To appreciate the reproducibly of these data, we analysed other Ig purified of serum 
specimens from additional breast cancer patients, with counterpart protein tissue. Therefore 
proteins from these breast cancer tissues were processed as describe above. As shown in 
cropped window (figure 31) among the proteins recognized from breast cancer Ig, the 
presence of three acidic α-enolase isoform has been confirmed and demonstrated by 
matching with the correspondent silver stained tissue. 
Development of high titers of autoantibody against enolase has been reported to be 
associated with a plethora of systemic or organ-specific autoimmune diseases (Gitlits VM 
et al. 2001), but also with different subtypes of lung cancer (Jankowska R et al. 2004, Li C 
et al. 2006), with melanoma (Suzuki A. et al. 2010) and endometriosis suggesting that it 
can be an immunogenic target in different typology of disease. 
 
 
Figure 31: 2D western blot with purified serum of 6 different breast cancer  patients to confirm the presence 
of enolase autoantibodies. 
 
In addition to comprehend if auto-antibodies anti-enolase proteins were exclusive present 
in breast cancer serum and not in the normal one, we analysed sera from disease-free 
patients. Ig from healthy volunteers were also purified by our immunoprecipitation 
technique and used as primary antibodies for 2D WB with the same protein breast cancer 
tissues used for previous assays. 
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As shown from the cropped images (figure 32),Ig isolated from healthy volunteers sera did 
not contain auto-antibodies direct against α-enolase proteins. 
 
Figure 32: 2D western blot with normal sera on 4 different breast cancer tissues. 
 
In fact free disease patients do not contain auto-antibodies against α-enolase, while sera 
from cancer patient contain auto-antibodies that strongly react with breast cancer tissue 
proteins.  
In conclusion, although Immunoproteomics remains of difficult interpretation, it allows us 
to identify different isoform of proteins, thus suggesting that this technique has the 
advantage to recognized the post-translational modification of the proteins. 
Finally, this results strongly suggest to consider that auto-antibodies direct against α-
enolase as potential biomarkers, as already seen for different neoplastic disease 
(Jankowska R et al. 2004, Suzuki A. et al. 2010) facilitating, in the future, the early 
diagnosis of breast cancer.  
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MATERIALS AND METHODS 
 
Clinical specimens 
The present study was conducted on 100 surgical tissues of ductal infiltrating breast cancer 
collected between 2003 and 2007 in the Breast Unit of the La Maddalena Hospital. 
Research was carried out in compliance with the Helsinki Declaration with the patients‘ 
written consent. 
The study used leftover specimens, that is, aliquots of specimens collected for routine 
clinical care, and immediately frozen at -80°C until used. The specimens were not 
individually identifiable. 
The patients of this study did not receive any cytotoxic/endocrine treatment prior to 
surgery. Diagnosis of ductal breast cancer (G2/G3) was confirmed histopathologically. 
Post-operative monitoring to define whether or not distant metastases were present, was 
performed by conventional imaging follow-up, consisting of chest radiography, bone 
scintigraphy, magnetic resonance imaging (MRI) and positron emission tomography using 
2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG-PET), as clinically indicated at La 
Maddalena Hospital. 
 
Sample preparations 
The frozen breast tissue samples were washed several times with phosphate-buffered saline 
and homogenized in RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% 
deoxycholate, 150 mM  NaCl, 4 mM EDTA) containing a mixture of protease inhibitors 
(0.01% aprotinin,10 mM sodium pyrophosphate, 2 mM sodium orthovanadate,1 mM 
PMSF). The extraction was carried out overnight at 4°C with the same buffer. The total 
cellular lysate was centrifuged to remove tissue debris, and the resulting supernatant 
dialysed against ultrapure distilled water, lyophilized and stored at -80°C until use. The 
total protein concentration was determined by the Bradford method using bovine serum 
albumin as a standard. 
 
Two Dimensional Gel Electrophoresis 
The proteins extracted from breast cancer tissue and normal adjacent tissue were 
solubilised in a buffer containing 4% CHAPS, 40 mM Tris, 65 mM DTE in 8 M urea. 
Aliquots of 45 μg (analytical gels) or 1.5 mg (preparative gels) of total proteins were 
separately mixed with 350 μL of rehydration solution containing 8 M urea, 2% CHAPS, 10 
mM DTE and 0.5% carrier anpholytes (Resolyte 3.5-10), and applied for IEF using 
commercial sigmoidal IPG strips, 18 cm long with pH range 3.0-10. The second dimension 
was carried out on 9-16% linear gradient polyacrylamide gels (SDS-PAGE), and the 
separated proteins were visualized by ammoniacal silver staining. Stained gels were 
digitized using a computing densitometer and analyzed with Image Master software 
(Amersham Biosciences, Sweden). Gel calibration was carried out using an internal 
standard and the support of the ExPaSy molecular biology server, as described [16]. 
 
Protein identification 
N-Terminal microsequencing was performed by automated Edman degradation in a protein 
sequencer (Procise, 419 Applied Biosystems), as previously described (Pucci-Minafra I et 
al. 2002). 
Mass spectrometric sequencing was performed by Voyager DE-PRO (Applied Biosystems) 
mass spectrometer as described. Briefly, proteins were digested using sequencing-grade 
trypsin (20 μg/vial). The tryptic peptide extracts were dried and redissolved in 10 μL of 
0.1% trifluoroacetic acid (TFA). The matrix, R-cyano-4-hydroxycinnamic acid (HCCA), 
was purchased from Sigma-Aldrich. A saturated solution of HCCA (1 μL) at 2 mg/200 μL 
in CH3CN/H2O (50:50 (v/v)) containing 0.1% TFA was mixed with 1 μL of peptide 
solution on the MALDI plate and left to dry. MALDI-TOF mass spectra were recorded in 
the 500-5000 Da mass range, using a minimum of 100 shots of laser per spectrum. Delayed 
extraction source and reflector equipment allowed sufficient resolution to consider MH+ of 
monoisotopic peptide masses. Internal calibration was done using trypsin autolysis 
fragments at m/z 842.5100, 1045.5642, and 2211.1046 Da. Peptide mass fingerprinting 
was compared to the theoretical masses from the Swiss-Prot or NCBI sequence databases 
using Mascot http://www.matrixscience.com/. Typical search parameters were as follows: 
(50 ppm of mass tolerance, carbamidomethylation of cysteine residues, one missed 
enzymatic cleavage for trypsin, a minimum of four peptide mass hits was required for a 
match, methionine residues could be considered in oxidized form. 
 
Western Blotting of S100 proteins 
For immune detection the gels were electrotransferred onto nitrocellulose membrane 
(HyBond ECL, Amersham) and stained with Ponceau S (Sigma). The membranes were 
then probed with one of the following monoclonal antibodies: anti-actin (Oncogene), anti-
S100A2, anti-S100A4, anti-S100A6, anti-S100A7, anti-S100A8 (Santa Cruz), or 
polyclonal antibodies: anti-S100A11, anti-S100A13 (SantaCruz). Following incubation 
with the appropriate peroxidase-linked antibody, the reaction was revealed by the ECL 
detection system, using high performance films (Hyperfilm ECL, Amersham). 
 
Quantification and normalization methods 
Quantitative expression levels were calculated as the volume of the spots (i.e. integration 
of optical density over the spot area). In order to correct for differences in gel staining, spot 
volumes relative to the sum of the volume of all spots an each gel (%Vol) were calculated 
by the software. Since the cell densities within an area of the surgical sample, may be very 
variable among the different patients, measurements of relative expression levels of 
individual protein spots were normalized in each map for actin content (Pucci-Minafra et 
al. 2008) and the final value was designated as N%V. For statistical analyses Ms Excel and 
Graph Pad Prism 4 software were used. Correlation of S100 protein members for breast 
cancer patients was performed using the Pearson correlation test. The difference in S100 
expression between metastatic versus disease free patients was analyzed by unpaired F test. 
In all cases, p < 0.05 was considered significant (*), p < 0.01 highly significant (**) and p 
< 0.001 very highly significant (***). 
 
Purification of Ig from serum with Protein A 
To favourite the bond between protein A and serum Ig, 10 μl of Protein A (GE Healthcare) 
has been incubated with 50 μl of H2O, 50 μl of serum and 50 μl of Immunoprecipitation 
Buffer (2% Triton X-100, 300 mM NaCl, 20 mM Tris pH 7.4, 2 mM EDTA, 2 mM EGTA, 
0.4 mM sodio ortho vanadato, 0.4 mM PMSF e 1% NP-40) for 30‘ at 4°C. 
After centrifugation of 2 minutes at 13,000 rpm, the pellet was washed 3 times in 
Immunoprecipitation Buffer to remove the non-specific interactions. Protein A bounded to 
Ig was then resuspended in 30 μl of Eluition Buffer (0.1 M citric acid pH 3.0) for 15 min at 
4 ° C to allow the separation of IgG and then centrifuged for 2 minutes at 13,000 rpm. The 
eluate was then diluted in 1% milk (in TBS-T 0.05% Tween) and used as primary 
antibody. 
 
Immunoprecipitation of tissue proteins 
In order to immunoprecipitate antigens, contained in the cell lysate, from tissues of breast 
cancer, immunoglobulins from autologous serum were bound to protein A, as described 
previously. 
To the protein A-conjugated Ig of the serum were added 300 μg of total protein extracted 
from tumor tissue of the same patient with 50 μl of Immunoprecipitation Buffer. The 
suspension was incubated 1 hour at 4 ° C and then centrifuged for 2 minutes at 13,000 rpm, 
removing the supernatant. Then three washes were performed with 50 μl each of 
Immunoprecipitation Buffer and centrifuged each time for 2 minutes at 13000 rpm. 
Finally, were added 30 μl of Eluition Buffer for 15 minutes at 4 ° C with shaking and 
centrifuged for 2 min. at 13000 rpm, each time recovering the supernatant. The operation 
was repeated 3 times. The eluate was dialyzed, lyophilized and resuspended in rehydration 
solution and loaded into two-dimensional electrophoresis. 
  
CONCLUSIONS 
 
In order to identify novel protein clusters in breast cancer tissues potentially involved in 
tumor progression, the first part of my thesis regarded the increase, up to 100 breast cancer 
tissues, of samples studied, followed by a gene ontology study performed with DAVID 
Bioinformatics Resources. A redundant list of categories was generated, including the gene 
cluster of regulation of programmed cell death, cell motion cluster and glycolysis were at 
first places for robustness. 
The combination of experimental proteomics with bioinformatics has produced 
information of great interest. In particular, the general expression pattern of proteins 
involved in anti-apoptotic and glycolysis pathways confirms respectively the cell survival-
dependence for primary tumor growth and the altered metabolism of tumoral cells, while 
the irregular expression of proteins involved in cell motility, clearly demonstrated the 
heterogeneity of metastatic potentialities and suggests the possibility of using some of the 
motion cluster proteins as prognostic factors for metastasis propens. 
Subsequently my study focalized on the S100 family, that is emerging as a potentially 
important group of markers in multiple tumour types. we verified a significant deregulation 
of most S100 member in breast cancer tissues compared with non-tumoral tissues adjacent 
to the primary tumor in which these proteins are very low or absent. Most of the detected 
S100 members appeared reciprocally correlated suggesting therefore common pathways of 
(dys)-regulation. Finally patients which developed distant metastases after a three year 
follow-up showed a general tendency of higher S100 protein expression, compared to the 
disease-free group resulting be associated with breast cancer progression. Among these, 
S100A7 (isoform a) showed the most robust correlation with metastases, a sporadic 
protein, expressed only in about 20% of the patients but when present, shows a remarkable 
intensity, suggesting therefore its potential role as biomarker for patient stratification. 
Then, although the function of these proteins into the cells is still unknown, we believe that 
this information may substantially contribute to the progress of protein profiling of breast 
cancer for clinical applications. 
Finally we use SERPA approach to identify autoantibodies circulating in cancer sera, that 
recognize antigenic protein and may serve as novel markers in screening, diagnosis or in 
prognosis. 
In this study we have combined a proteomic approach with an immunological method to 
find autoantibodies direct against tumor antigens that elicit humoral immune response in 
the sera derived from breast cancer patients. Through SERological Proteome Analysis 
(SERPA) approach indeed we identified antibodies direct against α-enolase in several 
serum of breast cancer patient suggesting that autoantibodies have potential as biomarkers 
and may in future facilitate the early diagnosis of breast cancer. Moreover multiple studies 
demonstrated that autoantibodies are tumor-associated and the molecules recognized as 
autoantigens in cancer sera are frequently overexpressed in tumor tissue. 
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